Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Study Summary

The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with chemotherapy or after radiation therapy.